About Guanine nucleotide-binding protein G(i) subunit alpha-2
Guanine nucleotide-binding protein G(i) subunit alpha-2 (GNAI2) is a protein
from Homo sapiens identified by UniProt accession
P04899, 355 residues long.
MolForge cross-references it against 0 known binders and
373 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein G(i) subunit alpha-2 |
| UniProt accession | P04899 |
| Gene | GNAI2 |
| Organism | Homo sapiens |
| Length | 355 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (373)
Diseases linked to this target (Open Targets).
- Ovarian Granulosa Cell Tumor · score 0.42
- ovarian granulosa tumour · score 0.42
- adrenal cortex carcinoma · score 0.42
- pituitary-dependent Cushing's disease · score 0.33
- ventricular tachycardia · score 0.33
- non-Hodgkins lymphoma · score 0.30
- hypopituitarism · score 0.27
- Motor delay · score 0.27
- Recurrent infections · score 0.27
- Decreased circulating total IgM · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P04899-F1 | alphafold | PREDICTED | 94.08 | — |
Amino-acid sequence (355 residues)
MGCTVSAEDK AAAERSKMID KNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEDG YSEEECRQYR AVVYSNTIQS IMAIVKAMGN LQIDFADPSR ADDARQLFAL SCTAEEQGVL PDDLSGVIRR LWADHGVQAC FGRSREYQLN DSAAYYLNDL ERIAQSDYIP TQQDVLRTRV KTTGIVETHF TFKDLHFKMF DVGGQRSERK KWIHCFEGVT AIIFCVALSA YDLVLAEDEE MNRMHESMKL FDSICNNKWF TDTSIILFLN KKDLFEEKIT HSPLTICFPE YTGANKYDEA ASYIQSKFED LNKRKDTKEI YTHFTCATDT KNVQFVFDAV TDVIIKNNLK DCGLF
Explore Guanine nucleotide-binding protein G(i) subunit alpha-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets